ECSP10010430A - Ciertas Entidades Químicas, Composiciones y Procedimientos - Google Patents
Ciertas Entidades Químicas, Composiciones y ProcedimientosInfo
- Publication number
- ECSP10010430A ECSP10010430A EC2010010430A ECSP10010430A ECSP10010430A EC SP10010430 A ECSP10010430 A EC SP10010430A EC 2010010430 A EC2010010430 A EC 2010010430A EC SP10010430 A ECSP10010430 A EC SP10010430A EC SP10010430 A ECSP10010430 A EC SP10010430A
- Authority
- EC
- Ecuador
- Prior art keywords
- skeletal
- muscle
- chemical entities
- certain chemical
- procedures
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000005829 chemical entities Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 210000003205 muscle Anatomy 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 102000013534 Troponin C Human genes 0.000 abstract 1
- 102000013394 Troponin I Human genes 0.000 abstract 1
- 108010065729 Troponin I Proteins 0.000 abstract 1
- 102000004987 Troponin T Human genes 0.000 abstract 1
- 108090001108 Troponin T Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 208000024980 claudication Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000002235 sarcomere Anatomy 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2606708P | 2008-02-04 | 2008-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010430A true ECSP10010430A (es) | 2011-02-28 |
Family
ID=40952391
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010430A ECSP10010430A (es) | 2008-02-04 | 2010-08-27 | Ciertas Entidades Químicas, Composiciones y Procedimientos |
| EC2010010432A ECSP10010432A (es) | 2008-02-04 | 2010-08-30 | Método para la mejora de la recuperación de hidrocarburos pesados |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010432A ECSP10010432A (es) | 2008-02-04 | 2010-08-30 | Método para la mejora de la recuperación de hidrocarburos pesados |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7989469B2 (https=) |
| EP (1) | EP2244711A4 (https=) |
| JP (1) | JP2011510985A (https=) |
| KR (1) | KR20100119773A (https=) |
| CN (1) | CN101983061A (https=) |
| AR (1) | AR072242A1 (https=) |
| AU (1) | AU2009210787A1 (https=) |
| BR (1) | BRPI0907502A2 (https=) |
| CA (1) | CA2713864A1 (https=) |
| CL (1) | CL2009000246A1 (https=) |
| CO (1) | CO6290673A2 (https=) |
| EA (1) | EA201001224A1 (https=) |
| EC (2) | ECSP10010430A (https=) |
| IL (1) | IL207367A0 (https=) |
| MX (1) | MX2010008518A (https=) |
| TW (1) | TW200946524A (https=) |
| WO (1) | WO2009099594A1 (https=) |
| ZA (1) | ZA201005780B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| EP2730575B1 (en) * | 2011-07-09 | 2015-09-16 | Xuanzhu Pharma Co., Ltd. | Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof |
| KR101951220B1 (ko) | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| CN111840294A (zh) * | 2012-04-11 | 2020-10-30 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力的方法 |
| HUE057533T2 (hu) | 2014-04-29 | 2022-05-28 | Cytokinetics Inc | Eljárások vitálkapacitás csökkenésének gátlására |
| TWI794369B (zh) * | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| TW201927738A (zh) * | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| CA3141571A1 (en) | 2019-05-28 | 2020-12-03 | Mankind Pharma Ltd. | 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 |
| EP4333982A1 (en) * | 2021-05-06 | 2024-03-13 | Exscientia Al Limited | Pkc-theta modulators |
| CN118702622A (zh) * | 2024-08-30 | 2024-09-27 | 阜新达得利化工股份有限公司 | 一种3-溴-2-氰基吡啶的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| US20040166137A1 (en) * | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| EP1646614A4 (en) * | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| US20050250794A1 (en) * | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
| JP2007529422A (ja) * | 2004-01-29 | 2007-10-25 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 抗ウイルス治療 |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| ES2558517T3 (es) * | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| ATE543819T1 (de) * | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| WO2008075007A1 (en) * | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| WO2008121333A1 (en) * | 2007-03-30 | 2008-10-09 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| US7998976B2 (en) * | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CA2744498C (en) | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
-
2009
- 2009-02-02 EP EP09708594A patent/EP2244711A4/en not_active Withdrawn
- 2009-02-02 CA CA2713864A patent/CA2713864A1/en not_active Abandoned
- 2009-02-02 MX MX2010008518A patent/MX2010008518A/es not_active Application Discontinuation
- 2009-02-02 JP JP2010545031A patent/JP2011510985A/ja not_active Withdrawn
- 2009-02-02 EA EA201001224A patent/EA201001224A1/ru unknown
- 2009-02-02 US US12/364,394 patent/US7989469B2/en not_active Expired - Fee Related
- 2009-02-02 AU AU2009210787A patent/AU2009210787A1/en not_active Abandoned
- 2009-02-02 KR KR1020107018611A patent/KR20100119773A/ko not_active Withdrawn
- 2009-02-02 BR BRPI0907502A patent/BRPI0907502A2/pt not_active Application Discontinuation
- 2009-02-02 CN CN2009801121602A patent/CN101983061A/zh active Pending
- 2009-02-02 WO PCT/US2009/000686 patent/WO2009099594A1/en not_active Ceased
- 2009-02-03 TW TW098103382A patent/TW200946524A/zh unknown
- 2009-02-04 AR ARP090100372A patent/AR072242A1/es unknown
- 2009-02-04 CL CL2009000246A patent/CL2009000246A1/es unknown
-
2010
- 2010-08-02 IL IL207367A patent/IL207367A0/en unknown
- 2010-08-13 ZA ZA2010/05780A patent/ZA201005780B/en unknown
- 2010-08-27 EC EC2010010430A patent/ECSP10010430A/es unknown
- 2010-08-30 EC EC2010010432A patent/ECSP10010432A/es unknown
- 2010-08-30 CO CO10106625A patent/CO6290673A2/es not_active Application Discontinuation
-
2011
- 2011-06-21 US US13/165,281 patent/US20110312975A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090253737A1 (en) | 2009-10-08 |
| CL2009000246A1 (es) | 2009-06-26 |
| ZA201005780B (en) | 2011-04-28 |
| IL207367A0 (en) | 2010-12-30 |
| WO2009099594A1 (en) | 2009-08-13 |
| MX2010008518A (es) | 2010-11-10 |
| EP2244711A1 (en) | 2010-11-03 |
| EA201001224A1 (ru) | 2011-08-30 |
| JP2011510985A (ja) | 2011-04-07 |
| ECSP10010432A (es) | 2011-01-31 |
| US7989469B2 (en) | 2011-08-02 |
| US20110312975A1 (en) | 2011-12-22 |
| CN101983061A (zh) | 2011-03-02 |
| TW200946524A (en) | 2009-11-16 |
| CO6290673A2 (es) | 2011-06-20 |
| BRPI0907502A2 (pt) | 2019-01-15 |
| KR20100119773A (ko) | 2010-11-10 |
| CA2713864A1 (en) | 2009-08-13 |
| EP2244711A4 (en) | 2011-08-24 |
| AU2009210787A1 (en) | 2009-08-13 |
| AR072242A1 (es) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010430A (es) | Ciertas Entidades Químicas, Composiciones y Procedimientos | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| CL2008002916A1 (es) | Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros. | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| EA201491666A1 (ru) | Способы повышения устойчивости скелетных мышц к утомлению | |
| BR112015024846A2 (pt) | composições para utilização no estímulo do crescimento ósseo | |
| MX357528B (es) | Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales. | |
| PE20150954A1 (es) | Proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina | |
| UY30454A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
| BR112014005358A2 (pt) | composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização | |
| CL2014000801A1 (es) | Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos. | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| SV2010003556A (es) | Moleculas y metodos para modular el componente de complemento | |
| ECSP13012573A (es) | 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3 | |
| UY30468A1 (es) | Compuestos quimicos. | |
| UY31540A1 (es) | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 | |
| CU20120171A7 (es) | Triazolopiridinas sustituidas | |
| EA201891754A1 (ru) | Композиции гиалуроновой кислоты, включающие мепивакаин | |
| BR112016007487A2 (pt) | composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica | |
| PH12014502711A1 (en) | Compositions and methods for enhancing mobilization and proliferation of blastomere-like stem cells | |
| BR112015012581A2 (pt) | análogos de ravioli e métodos para fazer tais análogos | |
| ECSP13012453A (es) | 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3 |